Published in Health Business Week, January 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Peplin.
Report 1: Peplin Limited (PEP) has initiated proceedings to secure its tenancy of the J. H. Aylward manufacturing facility in Southport, Queensland.
The manufacturing facility is Peplin's recently commissioned and licensed facility for the production of PEP005, the active ingredient in PEP005 Topical, its proprietary product being developed for the treatment of actinic (solar) keratosis and basal cell carcinoma, the most common form of skin cancer. The facility was opened...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.